We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER and CBER Issue Guidance on Drug Trials Targeting Chronic Rhinosinusitis
CDER and CBER Issue Guidance on Drug Trials Targeting Chronic Rhinosinusitis
In a draft guidance released yesterday, the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) offer advice for sponsors on the development of drugs or biological products for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).